Search International and National Patent Collections

1. (WO2017202851) SECRETIN RECEPTOR AGONISTS TO TREAT DISEASES OR DISORDERS OF ENERGY HOMEOSTASIS

Pub. No.:    WO/2017/202851    International Application No.:    PCT/EP2017/062420
Publication Date: Fri Dec 01 00:59:59 CET 2017 International Filing Date: Wed May 24 01:59:59 CEST 2017
IPC: C07K 14/645
A61K 38/00
C07K 14/72
G01N 33/74
Applicants: TECHNISCHE UNIVERSITÄT MÜNCHEN
Inventors: KLINGENSPOR, Martin
GABLER, Sarah-Madeleine
LI, Yongguo
Title: SECRETIN RECEPTOR AGONISTS TO TREAT DISEASES OR DISORDERS OF ENERGY HOMEOSTASIS
Abstract:
The present invention relates to a secretin receptor modulator for use in the prevention and/or treatment of a disease or disorder of energy homeostasis, wherein (a) said secretin receptor modulator is a secretin receptor agonist and said disease or disorder is obesity, dyslipidemia, diabetes, insulin resistance, hyperglycemia, high blood pressure or metabolic syndrome, whereby the secretin receptor agonist increases non-shivering thermogenesis in brown adipocytes and/or increases the expression of uncoupling protein 1 (UCP1) in brown adipocytes and/or decreases food intake in a UCP1 -dependent manner resulting in the prevention and/or treatment of said disease or disorder; or (b) said secretin receptor modulator is a secretin receptor antagonist and said disease or disorder is cachexia. The invention further relates to a method of increasing non-shivering thermogenesis in brown adipocytes and/or increasing the expression of uncoupling protein 1 (UCP1 ) in brown adipocytes, to a method of decreasing non-shivering thermogenesis in brown adipocytes, to a method of identifying a secretin receptor agonist capable of increasing non-shivering thermogenesis in brown adipocytes and/or increasing the expression of uncoupling protein 1 (UCP1 ) in brown adipocytes, to a method of identifying a secretin receptor antagonist capable of decreasing non-shivering thermogenesis in brown adipocytes, to the use of the secretin receptor for screening (a) for secretin receptor agonists that increase non-shivering thermogenesis in brown adipocytes and/or increase the expression of uncoupling protein 1 (UCP1 ) in brown adipocytes and/or decrease food intake in a UCP1 -dependent manner; and/or (b) for secretin receptor antagonists that decrease non-shivering thermogenesis in brown adipocytes, and to the use of a secretin receptor agonist to activate non-shivering thermogenesis in brown adipocytes and/or to increase the expression of uncoupling protein 1 (UCP1 ) in brown adipocytes and/or to decrease food intake in a UCP1 -dependent manner for reducing body weight for cosmetic purposes as well as to the use of a secretin receptor antagonist to decrease thermogenesis in brown adipocytes for increasing body weight for cosmetic purposes.